Aron Mosnaim

Neuroscientist

Aron David Mosnaim

Occupation(s)| Neuroscientist, researcher, and academic
Academic background
Education| PharmD degree
PhD in Organic Chemistry
Alma mater| University of Chile
University of Strathclyde
Academic work
Institutions| Rosalind Franklin University of Medicine and Science
International Neuropsychiatry Consultants

Aron David Mosnaim is a neuroscientist, researcher, and academic. He is a professor of Cellular and Molecular Pharmacology and an adjunct professor of Psychiatry and Behavioral Sciences in the Chicago Medical School at Rosalind Franklin University of Medicine and Science.[1]

Mosnaim is most known for his research covering the areas of basic and clinical neuro\- and immunopharmacology of biogenic amines and opioid peptides in neuropsychiatric conditions, including depression, headache pain, as well as movement and posttraumatic stress disorders.[2] He has co-edited four scientific books on Noncatecholic Phenylethylamines (2 volumes),[3] Posttraumatic Stress Disorder,[4] and Tardive Dyskinesia.[5]

Mosnaim has served as a Consultant to the Pan American Health Organization (1982–1985), Member of the United States Pharmacopeia Convention (1990 and 1995), and Director of International Neuropsychiatry Consultants (1987–2020). Additionally, he is a Fellow of The Chemical Society (1977) and a Senior Fellow of the American Institute of Therapeutics (2019).[1]

## Early life and education[edit]

Mosnaim earned a Doctor of Pharmaceutical Sciences degree from the University of Chile (1964) and joined the Faculty of the university's School of Medicine. He was awarded a PhD degree in Organic Chemistry from Glasgow’s Strathclyde University (1969). After a brief tenure at the University of Chicago, he received a postdoctoral fellowship at Northwestern University (1970).[2]

## Career[edit]

In 1971, Mosnaim joined the University of Health Sciences/The Chicago Medical School as an assistant professor in the Department of Pharmacology. He was promoted to Associate Professor and Acting Chairman (1974), and to a Full Professorship in 1979. He has been serving as a professor of Cellular and Molecular Pharmacology and adjunct professor of Psychiatry and Behavioral Sciences at The Chicago Medical School/Rosalind Franklin University.[1]

Mosnaim holds an Honorary Full Professorship at the University of Chile College of Pharmaceutical Sciences.

## Research[edit]

Mosnaim has published over 150 papers in peer-reviewed Journals, more than 20 invited reviews and book chapters, and presented research in more than 200 scientific meetings.[2]

Early in his research career (1967), Mosnaim contributed to elucidate the metabolic pathway of the then widely used toxic insecticide DDT (dichlorodiphenyltrichloroethane), and in a series of publications (1969–1972) helped to understand the mechanism of halogenation by cupric salts of carcinogenic anthracene and pyrene compounds.[6] His laboratory demonstrated the presence of phenylethylamine, commonly viewed as the endogenous amphetamine, in mammalian tissues, and his work elucidated this amine’s in vivo and in vitro brain metabolic pathway.[7][8][9] His work, animal models, contributed to establish phenylethylamine brain levels as a biological marker for various neuropsychiatric disorders, and to evaluate its brain changes in response to different classes of psychotropic drugs.[10][11] Further research identified some of the physiological functions, and described relevant behavior and toxicological effects of phenylethylamine and various structurally related trace amines.[12][13]

Mosnaim reported plasma levels of the endogenous opioid pentapeptide methionine-enkephalin in various patient populations, and the effect of selected classes of drugs on its degradation kinetics,[14] suggesting that its significant increase in chronic cluster and migraine patients during an acute headache episode could serve as a biological marker for these illnesses.[15][16] He also clarified reports of the activity of platelet monoamine oxidase and the role of dietary phenylethylamine and tyramine in the etiology of migraine headaches.[17]

Mosnaim contributed to document the association of tardive dyskinesia and drug-induced parkinsonism, and in identifying sub-types, cognitive deficits, and some of the risk factors associated with increased vulnerability to this condition.[18][19][20][21] He participated in studies finding comorbidity of pain, dermatological and allergic conditions, as well as decreased natural killer cell activity, in posttraumatic stress disorder patients.[22] He reported the decrease of this immune function in septic shock and human immunodeficiency virus-1 positive individuals, as well as its significant increase by various substances with widely different chemical structures and biological activities, e.g., enkephalins, α-interferon, interleukin-2, taxol, and lipopolysaccharide.[23][24][25]

## Bibliography[edit]

### Selected edited books[edit]

* Noncatecholic phenylethylamines Part 1 (1978) ISBN 0-8247-6616-4
* Noncatecholic phenylethylamines Part 2 (1980) ISBN 0-8247-6721-7
* Tardive Dyskinesia: Biological Mechanisms & Clinical Aspects (1989) ISBN O-8804-8176-5
* Posttraumatic Stress Disorder: Etiology, Phenomenology, and Treatment (1990) ISBN 0-8804-8299-0

### Selected articles[edit]

* Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. S2CID 8349615.
* Sabelli, Hector C.; Mosnaim, A. David (June 1974). "Phenylethylamine Hypothesis of Affective Behavior". American Journal of Psychiatry. 131 (6): 695–699. doi:10.1176/ajp.131.6.695. PMID 4827802.
* Wolf, Marion E; Alavi, Afshin; Mosnaim, Aron D (March 1988). "Posttraumatic stress disorder in vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine". Biological Psychiatry. 23 (6): 642–644. doi:10.1016/0006-3223(88)90011-x. PMID 3355879. S2CID 40512787.
* Mosnaim, Aron D.; Ranade, Vasant V.; Wolf, Marion E.; Puente, Javier; Antonieta Valenzuela, M. (May 2006). "Phenothiazine Molecule Provides the Basic Chemical Structure for Various Classes of Pharmacotherapeutic Agents". American Journal of Therapeutics. 13 (3): 261–273. doi:10.1097/01.mjt.0000212897.20458.63. PMID 16772768.

## References[edit]

1. ^ a b c "Aron D. Mosnaim, PhD". Rosalind Franklin University.
2. ^ a b c "Aron D Mosnaim". Walsh Medical Media.
3. ^ Noncatecholic phenylethylamines. OCLC 3516955.[page needed][non-primary source needed]
4. ^ Kinzie, J. David (October 1991). "Posttraumatic stress disorder: Etiology, phenomenology and treatment. By M. E. Wolf, and A. D. Mosnaim, editors. Washington, D.C.: American Psychiatric Press, Inc., 1990, 270 pages". Journal of Traumatic Stress. 4 (4): 607–608. doi:10.1002/jts.2490040416.
5. ^ Wolf, Marion E.; Mosnaim, Aron D. (1988). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press. ISBN 978-0-88048-176-2. OCLC 17953812.[page needed][non-primary source needed]
6. ^ Mosnaim, A.D.; Wolf, M.E.; Saavedra, I.; Amaro, A.M.; Cordano, G.; Nonhebel, D.C. (January 1973). "Reaction of cupric(ii) halides with organic compounds-VIII pyrene and some 3-substituted pyrenes". Tetrahedron Letters. 14 (17): 1491–1494. doi:10.1016/S0040-4039(01)95980-5.[non-primary source needed]
7. ^ Mosnaim, AD; Inwang, EE; Sugerman, JH; DeMartini, WJ; Sabelli, HC (June 1973). "Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression". Biological Psychiatry. 6 (3): 235–57. PMID 4732254.[non-primary source needed]
8. ^ Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. S2CID 8349615.[non-primary source needed]
9. ^ Mosnaim, Aron D.; Wolf, Marion E. (1978). Noncatecholic Phenylethylamines. M. Dekker. ISBN 978-0-8247-6616-0.[page needed][non-primary source needed]
10. ^ Wolf, Marion E.; Mosnaim, A.D. (January 1983). "Phenylethylamine in neuropsychiatric disorders". General Pharmacology: The Vascular System. 14 (4): 385–390. doi:10.1016/0306-3623(83)90020-4. PMID 6352395.[non-primary source needed]
11. ^ Sabelli, H. C.; Vazquez, A. J.; Mosnaim, A. D.; Madrid-Pedemonte, L. (March 1974). "2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation". Nature. 248 (5444): 144–145. Bibcode:1974Natur.248..144S. doi:10.1038/248144a0. PMID 4274244. S2CID 4168572.[non-primary source needed]
12. ^ Mosnaim, Aron D.; Callaghan, Owen H.; Hudzik, Thomas; Wolf, Marion E. (April 2013). "Rat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives". Neurochemical Research. 38 (4): 842–846. doi:10.1007/s11064-013-0988-1. PMID 23389662. S2CID 254860661.[non-primary source needed]
13. ^ Mosnaim, Aron D.; Wolf, Marion E.; III. O’Donnell, James J.; Hudzik, Thomas (3 July 2020). "β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice". Drug and Chemical Toxicology. 43 (4): 369–372. doi:10.1080/01480545.2018.1551899. PMID 30614291. S2CID 58557529.[non-primary source needed]
14. ^ Mosnaim, Aron D.; Puente, Javier; Saavedra, Rolando; Diamond, Seymour; Wolf, Marion E. (2003). "In vitro Human Plasma Leucine5-Enkephalin Degradation Is Inhibited by a Select Number of Drugs with the Phenothiazine Molecule in Their Chemical Structure". Pharmacology. 67 (1): 6–13. doi:10.1159/000066781. PMID 12444298. S2CID 22740728.[non-primary source needed]
15. ^ Mosnaim, Aron D.; Wolf, Marion E.; Chevesich, Jorge; Callaghan, Owen H.; Diamond, Seymour (July 1985). "Plasma Methionine Enkephalin Levels — A Biological Marker for Migraine?". Headache: The Journal of Head and Face Pain. 25 (5): 259–267. doi:10.1111/j.1526-4610.1985.hed2505259.x. PMID 4030316. S2CID 35728043.[non-primary source needed]
16. ^ Mosnaim, Aron D.; Diamond, Seymour; Freitag, Frederick; Chevesich, Jorge; Wolf, Marion E.; Solomon, Glen (June 1987). "Plasma and Platelet Methionine-Enkephalin Levels in Chronic Cluster Patients During an Acute Headache Episode". Headache: The Journal of Head and Face Pain. 27 (6): 325–328. doi:10.1111/j.1526-4610.1987.hed2706325.x. PMID 3654188. S2CID 29924147.[non-primary source needed]
17. ^ Mosnaim, A.D.; Freitag, F.; Karoum, F.; Wolf, M.E.; Diamond, S.; Salas, M.A. (April 1996). "Migraine and the contents of tyramine and phenylethylamine in food". Biological Psychiatry. 39 (7): 595. doi:10.1016/0006-3223(96)84270-3. S2CID 54244086.[non-primary source needed]
18. ^ Wolf, ME; Chevesich, J; Lehrer, E; Mosnaim, AD (October 1983). "The clinical association of tardive dyskinesia and drug-induced parkinsonism". Biological Psychiatry. 18 (10): 1181–8. PMID 6140032.[non-primary source needed]
19. ^ Wolf, Marion E.; Mosnaim, Aron D. (August 1984). "Identifying Subtypes of Tardive Dyskinesia". Psychiatric Services. 35 (8): 828–830. doi:10.1176/ps.35.8.828. PMID 6479919.[non-primary source needed]
20. ^ Wolf, Marion E.; Ryan, Joseph J.; Mosnaim, Aron D. (August 1983). "Cognitive functions in tardive dyskinesia". Psychological Medicine. 13 (3): 671–674. doi:10.1017/S0033291700048108. PMID 6137851. S2CID 26957713.[non-primary source needed]
21. ^ Wolf, ME; DeWolfe, AS; Ryan, JJ; Lips, O; Mosnaim, AD (September 1985). "Vulnerability to tardive dyskinesia". The Journal of Clinical Psychiatry. 46 (9): 367–8. PMID 2863257.[non-primary source needed]
22. ^ Wolf, M. E; Alavi, A.; Mosnaim, A. D. (1988). "Pain, dermatological and allergic conditions in post traumatic stress disorder". Pain, Dermatological and Allergic Conditions in Post Traumatic Stress Disorder. 13 (3): 237–240. INIST 7009885.[non-primary source needed]
23. ^ Maturana, Patricio; Puente, Javier; Miranda, Dante; Sepulveda, Cecilia; Wolf, Marion E.; Mosnaim, Aron D. (March 1991). "Natural killer cell activity in patients with septic shock". Journal of Critical Care. 6 (1): 42–45. doi:10.1016/0883-9441(91)90032-O.[non-primary source needed]
24. ^ Sepúlveda, Cecilia; Puente, Javier; Weinstein, Caroline; Wolf, Marion E.; Mosnaim, Aron D. (November 1997). "Enhancement of natural killer cell activity in HIV-1-infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester TPA: lack of response to a similar challenge with interleukin-2 or α-interferon". American Journal of Therapeutics. 4 (11): 413–422. doi:10.1097/00045391-199711000-00013. PMID 10423640. S2CID 42963577.[non-primary source needed]
25. ^ Puente, J; Carvajal, T; Parra, S; Miranda, D; Sepulveda, C; Wolf, ME; Mosnaim, AD (June 1993). "In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 31 (6): 271–275. PMID 8335423.[non-primary source needed]